Status:
COMPLETED
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-68 years
Brief Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects with type 2 diabete...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects with type 2 diabetes
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
1155 Patients enrolled
Trial Details
Trial ID
NCT01486875
Start Date
January 1 2006
End Date
January 1 2008
Last Update
January 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Lund, Sweden, 221 85